NCCN Guidelines for Patients® Version Updates: Prostate Cancer

Following are the major updates that were included in the NCCN Guidelines for Patients®: Prostate Cancer, Version 1.2015

  • Part 2 – Cancer staging
    • Page 12
      • Prostate MRI is discussed on this page. This test can be used at many points of care including cancer staging.
  • Part 3 – Treatment planning
    • Page 22
      • Molecular testing has been added. Such testing may help predict which prostate cancers that haven’t spread far might do so in the near future.
  • Part 4 – Overview of cancer treatments
    • Page 32
      • The recommendation for proton radiation therapy has been updated. This treatment is an option at cancer centers with the proper equipment and experience.
    • Page 32
      • Stereotactic body radiotherapy (SBRT, for short) has been added as an option to be carefully decided. If chosen, it should be received at cancer centers with the proper equipment and experience.
  • Part 5 – Treatment guide: Initial treatment
    • Pages 42
      • The criteria for very-high risk cancers have been modified to be T3b or T4 tumor, primary Gleason grade 5, or more than 4 biopsy cores with Gleason scores between 8 and 10.
  • Part 7 – Treatment guide: Advanced cancer
    • Pages 72
      • Continuous ADT and docetaxel has been added as an early option for castration-sensitive, high volume M1 disease.